The University of Chicago Header Logo

Connection

Ezra Cohen to Animals

This is a "connection" page, showing publications Ezra Cohen has written about Animals.
Connection Strength

0.331
  1. Combination immunotherapy with TLR agonists and checkpoint inhibitors suppresses head and neck cancer. JCI Insight. 2017 09 21; 2(18).
    View in: PubMed
    Score: 0.038
  2. Lenvatinib in Advanced, Radioactive Iodine-Refractory, Differentiated Thyroid Carcinoma. Clin Cancer Res. 2015 Dec 15; 21(24):5420-6.
    View in: PubMed
    Score: 0.033
  3. Afatinib efficacy against squamous cell carcinoma of the head and neck cell lines in vitro and in vivo. Target Oncol. 2015 Dec; 10(4):501-8.
    View in: PubMed
    Score: 0.032
  4. Molecular phenotype predicts sensitivity of squamous cell carcinoma of the head and neck to epidermal growth factor receptor inhibition. Mol Oncol. 2013 Jun; 7(3):359-68.
    View in: PubMed
    Score: 0.027
  5. Novel targeted therapies in head and neck cancer. Expert Opin Investig Drugs. 2012 Mar; 21(3):281-95.
    View in: PubMed
    Score: 0.026
  6. Effect of complementary pathway blockade on efficacy of combination enzastaurin and rapamycin. Head Neck. 2011 Dec; 33(12):1774-82.
    View in: PubMed
    Score: 0.024
  7. Efficacy of the multi-kinase inhibitor enzastaurin is dependent on cellular signaling context. Mol Cancer Ther. 2010 Oct; 9(10):2814-24.
    View in: PubMed
    Score: 0.023
  8. A feed-forward loop involving protein kinase Calpha and microRNAs regulates tumor cell cycle. Cancer Res. 2009 Jan 01; 69(1):65-74.
    View in: PubMed
    Score: 0.021
  9. ONYX-015. Onyx Pharmaceuticals. Curr Opin Investig Drugs. 2001 Dec; 2(12):1770-5.
    View in: PubMed
    Score: 0.013
  10. Role of B Cells in Responses to Checkpoint Blockade Immunotherapy and Overall Survival of Cancer Patients. Clin Cancer Res. 2021 11 15; 27(22):6075-6082.
    View in: PubMed
    Score: 0.012
  11. Disruption of the HER3-PI3K-mTOR oncogenic signaling axis and PD-1 blockade as a multimodal precision immunotherapy in head and neck cancer. Nat Commun. 2021 04 22; 12(1):2383.
    View in: PubMed
    Score: 0.012
  12. B Cells Improve Overall Survival in HPV-Associated Squamous Cell Carcinomas and Are Activated by Radiation and PD-1 Blockade. Clin Cancer Res. 2020 07 01; 26(13):3345-3359.
    View in: PubMed
    Score: 0.011
  13. HPV16 E5 Mediates Resistance to PD-L1 Blockade and Can Be Targeted with Rimantadine in Head and Neck Cancer. Cancer Res. 2020 02 15; 80(4):732-746.
    View in: PubMed
    Score: 0.011
  14. Immune Modulation of Head and Neck Squamous Cell Carcinoma and the Tumor Microenvironment by Conventional Therapeutics. Clin Cancer Res. 2019 07 15; 25(14):4211-4223.
    View in: PubMed
    Score: 0.011
  15. PI3K? is a molecular switch that controls immune suppression. Nature. 2016 11 17; 539(7629):437-442.
    View in: PubMed
    Score: 0.009
  16. A Novel Peptide for Simultaneously Enhanced Treatment of Head and Neck Cancer and Mitigation of Oral Mucositis. PLoS One. 2016; 11(4):e0152995.
    View in: PubMed
    Score: 0.009
  17. A synthetic-lethality RNAi screen reveals an ERK-mTOR co-targeting pro-apoptotic switch in PIK3CA+ oral cancers. Oncotarget. 2016 Mar 08; 7(10):10696-709.
    View in: PubMed
    Score: 0.009
  18. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009 Apr 01; 69(7):3021-31.
    View in: PubMed
    Score: 0.005
  19. Epidermal growth factor receptor controls flat dysplastic aberrant crypt foci development and colon cancer progression in the rat azoxymethane model. Clin Cancer Res. 2008 Apr 15; 14(8):2253-62.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.